Depression and suicidality with VMAT2 inhibitors in tardive dyskinesia A signal detection from the FDA Adverse Events Reporting System

被引：0
|
作者：
Yokoi, Yuma [1 ,2 ]
Kashiwagi, Hiroko [3 ]
Funada, Daisuke [3 ]
Yamashita, Shingo [2 ]
Kubota, Chika [2 ]
机构：
[1] Natl Ctr Hosp, Natl Ctr Neurol & Psychiat, Clin Res & Educ Promot Div, Dept Educ Promot, Tokyo, Japan
[2] Natl Ctr Hosp, Natl Ctr Neurol & Psychiat, Dept Psychiat, Tokyo, Japan
[3] Natl Ctr Hosp, Natl Ctr Neurol & Psychiat, Dept Forens Psychiat, Tokyo, Japan
来源：
PSYCHIATRY AND CLINICAL NEUROSCIENCES REPORTS | 2023年 / 2卷 / 01期
关键词：
D O I：
10.1002/pcn5.79
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] VMAT2 inhibitors for the treatment of tardive dyskinesia
    Scorr, Laura M.
    Factor, Stewart A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2018, 389 : 43 - 47
  • [2] VMAT2 Inhibitors for the Treatment of Tardive Dyskinesia
    Warren, Barbara
    Vanderhoef, Dawn
    Johnson, Jessica
    ISSUES IN MENTAL HEALTH NURSING, 2022, 43 (01) : 22 - 31
  • [3] VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications
    Peckham, Alyssa M.
    Nicewonder, Jessica A.
    JOURNAL OF PHARMACY PRACTICE, 2019, 32 (04) : 450 - 457
  • [4] VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia
    Kim, Anne P.
    Baker, Danial E.
    Levien, Terri L.
    CONSULTANT PHARMACIST, 2018, 33 (04): : 201 - 209
  • [5] FEASIBILITY OF A COMPARATIVE META-ANALYSIS OF VMAT2 INHIBITORS FOR THE TREATMENT OF TARDIVE DYSKINESIA
    Caroff, S. M.
    Aggarwal, S.
    Yonan, C.
    VALUE IN HEALTH, 2017, 20 (05) : A189 - A189
  • [6] Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review
    Golsorkhi, Mohadese
    Koch, Jessa
    Pedouim, Farzin
    Frei, Karen
    Bondariyan, Niloofar
    Dashtipour, Khashayar
    TREMOR AND OTHER HYPERKINETIC MOVEMENTS, 2024, 14 : 1 - 12
  • [7] Real-World Use and Impact of VMAT2 Inhibitors in Patients with Tardive Dyskinesia
    Lundt, L.
    Franey, E.
    Yonan, C.
    MOVEMENT DISORDERS, 2020, 35 : S40 - S40
  • [8] Metoclopramide and tardive dyskinesia: A review of the FDA Adverse Event Reporting System.
    Shaffer, D
    Butterfield, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P24 - P24
  • [9] Risk of VMAT2 inhibitors on suicidality and parkinsonism: report utilizing the United States Food and Drug Administration adverse event reporting system
    Wong, Sabrina
    Le, Gia Han
    Kwan, Angela T. H.
    Rhee, Taeho Greg
    Teopiz, Kayla M.
    Ho, Roger C.
    Cao, Bing
    Rosenblat, Joshua D.
    Mansur, Rodrigo
    Mcintyre, Roger S.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2025, 40 (03) : 176 - 181
  • [10] Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective
    Citrome, Leslie
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2018, 18 (04) : 323 - 332
12345